BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP415464
下载链接
链接失效反馈官方服务：
资源简介：
We demonstrated that secondary Plasma Cell Leukemia, addicted to BCLXL, a small but a very challenging group of patients, could benefit from DT2216, underpinning its clinical evaluation. Overall design: RNA CD138 positive human plasma cells were extracted with RNeasy Mini Kit (Qiagen) and sequenced on 3'ends.
创建时间：
2024-05-01
